Jaguar8 commented on a stock · Oct 1, 2024 19:32

NEWS

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

• Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1)
◦ Patient Dosing Commenced 3Q Calendar Year 2024
◦ Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024
◦ Topline Results Expected 1Q Calendar Year 2025
• Dry Eye Disease (DED): PL9643
◦ MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies
▪ FDA Confirms Protocols and Endpoints
▪ Patient Enrollment Start Expected 1Q Calendar Year 2025
▪ Topline Results Anticipated 4Q Calendar Year 2025
◦ Potential Partner Collaboration and Funding Discussions Ongoing
• Male Sexual Dysfunction: Bremelanotide Co-Formulated with a PDE5i for the Treatment of Erectile Dysfunction (ED) in Patients That Do Not Respond to PDE5i Monotherapy
◦ Pharmacokinetics Study Expected to Start 1Q Calendar Year 2025
◦ Patient Recruitment in Phase 2/3 Study Anticipated in 2H Calendar Year 2025
• Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC Patients
◦ Interim Analysis Readout Expected 4Q Calendar Year 2024
◦ Topline Results Anticipated 1Q Calendar Year 2025
◦ Potential Partner Collaboration and Funding Discussions Ongoing
• Diabetic Nephropathy: Phase 2 BMT 701 Study in Patients with Diabetic Kidney Disease
◦ Topline Results Expected 4Q Calendar Year 2024
• Teleconference and Webcast to be held on October 1, 2024, at 11:00 AM ET

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

8652 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8158

Followers

Following

93K

Visitors